product
applic
nonrod
monoclon
antibodi
veterinari
scienc
vet
immunol
immunopathol
requir
monoclon
antibodi
deriv
speci
rat
mice
becom
increasingli
realis
veterinari
well
human
medicin
paper
review
current
knowledg
product
interspeci
hybridoma
heterohybridoma
fusion
rodent
myeloma
cell
line
lymphocyt
speci
veterinari
import
date
number
monoclon
immunoglobulin
deriv
sheep
cattl
pig
rabbit
mink
primat
speci
produc
varieti
differ
bacteri
viral
nematod
pathogen
well
blood
group
mhc
determin
hormon
techniqu
open
number
possibl
futur
applic
discuss
relat
antibodi
produc
thu
far
sinc
product
monoclon
antibodi
mab
first
describ
kshler
milstein
use
spread
nearli
everi
field
biolog
medic
scienc
mab
describ
date
rodent
origin
mani
instanc
mab
deriv
speci
would
advantag
one
use
would
administr
mab
therapeut
prophylact
purpos
rodent
mab
would
evok
immun
reaction
recipi
see
review
chatenoud
instanc
parasitolog
mab
requir
identifi
hostspecif
protect
antigen
parasit
kennedi
et
al
anderson
et
al
product
antiidiotyp
sack
dna
clone
express
system
udomsangpetch
et
al
studi
speciesspecif
immunoglobulin
ig
structur
organis
mab
deriv
tucker
et
al
dicker
et
al
beh
et
al
anderson
et
al
grove
et
al
anderson
et
al
grove
et
ak
davidson
et
al
srikumaran
et
al
tucker
et
al
guidri
et
al
raybould
et
al
anderson
et
al
guidri
et
al
tucker
et
al
cattl
anderson
et
al
grove
et
al
butcher
grove
et
al
kennedi
et
al
kemp
et
al
raybould
et
al
yarmush
et
al
kuo
et
al
raybould
takahashi
van
meum
jonker
stanley
rees
van
meur
jonker
galakhar
et
al
relev
speci
necessari
mab
also
use
product
antisera
isotyp
determin
well
provis
serolog
standard
srikumaran
et
al
moreov
isol
cell
line
produc
ig
make
possibl
clone
relev
gene
studi
transcript
translat
buckel
et
al
speciesspecif
carbohydr
group
ig
shown
import
sever
antibodi
effector
mechan
therefor
possibl
rodent
mab
may
execut
effector
function
complement
fixat
fc
bind
use
nonrod
speci
nose
wigzel
final
often
prove
difficult
make
mous
mab
recognis
allel
differ
exist
within
speci
crossspeci
immunis
overwhelm
respons
heterolog
antigen
antibodi
subtl
polymorph
determin
blood
group
mhc
determin
may
detect
kemp
et
al
human
medicin
much
research
conduct
product
human
mab
see
jame
bell
parallel
studi
investig
product
mab
deriv
econom
import
anim
speci
also
initi
purpos
review
bring
togeth
scatter
literatur
subject
assess
variou
methodolog
approach
use
date
discuss
futur
possibl
field
veterinari
medicin
establish
optimum
condit
product
mab
necessari
consid
natur
immunogen
immunis
protocol
sourc
lymphocyt
time
interv
immunis
collect
use
domest
anim
sourc
lymphocyt
possibl
employ
varieti
immunis
procedur
remov
spleen
lymph
node
surgeri
necessari
slaughter
anim
peripher
blood
lymphocyt
also
readili
obtain
consequ
scope
experiment
human
mab
product
tabl
show
procedur
use
date
differ
speci
lymphocyt
fusion
success
recov
varieti
sourc
local
secondari
stimul
lymph
node
anderson
et
al
tucker
et
al
kennedi
et
al
peripher
blood
grove
et
al
grove
et
al
b
spleen
srikumaran
et
al
raybould
et
al
b
gener
requir
immunis
produc
mab
polyclon
antibodi
depend
individu
circumst
time
fusion
follow
booster
dose
prime
import
may
well
vari
individu
speci
compar
studi
made
human
field
optimum
time
harvest
peripher
blood
lymphocyt
consid
day
bogard
et
al
day
spleen
lymphocyt
schwaber
et
al
tabl
show
time
use
product
nonrod
mab
veterinari
interest
usual
time
day
post
booster
dose
cattl
suitabl
immunis
schedul
prime
intramuscularli
antigen
freund
complet
adjuv
boost
delay
least
week
antigen
incomplet
adjuv
inject
subcutan
drain
lymph
node
three
day
later
lymph
node
remov
ie
time
antibodi
titr
rise
yet
reach
peak
anderson
et
al
cattl
sheep
peripher
blood
use
lymphocyt
sourc
collect
lymphocyt
day
post
boost
found
success
grove
et
al
ideal
myeloma
cell
line
deriv
speci
interest
would
fusion
partner
choic
product
nonrod
mab
howev
line
current
avail
although
lymphoblastoma
found
domest
speci
hors
cat
cattl
date
therefor
attent
direct
toward
construct
use
heterohybridoma
produc
mab
veterinari
interest
ie
fuse
rodent
myeloma
cell
lymphocyt
immunis
farm
domest
anim
major
problem
encount
heterohybridoma
although
usual
grow
well
cultur
like
interspecif
somat
cell
hybrid
chromosom
unstabl
lose
nonrod
chromosom
divid
weiss
green
even
heterohybridoma
initi
secret
desir
antibodi
therefor
ceas
lose
relev
chromosom
nevertheless
stabl
antibodysecret
line
produc
method
present
nonrod
monoclon
antibodi
interest
veterinari
scienc
produc
way
tabl
attempt
improv
stabil
sever
group
use
heterohybridoma
cell
line
fusion
partner
place
mous
rat
myeloma
tabl
fusion
partner
must
first
select
aminopterin
sensit
achiev
passag
cell
sever
month
presenc
pgml
littlefield
hasten
process
clone
hybridoma
soft
agar
presenc
tucker
et
al
techniqu
taken
well
primari
mous
x
speci
sp
heterohybridoma
secondari
mous
sp
sp
even
tertiari
mous
x
sp
sp
sp
cell
line
construct
aim
increas
number
nonrod
chromosom
retain
refus
procedur
result
increas
bovin
chromosom
primari
secondari
tertiari
heterohybridoma
anderson
et
al
howev
concomit
increas
number
polyploid
cell
cell
popul
becam
increasingli
heterogen
size
result
demonstr
least
cattl
anderson
et
al
grove
et
al
tucker
et
al
possibl
sheep
anderson
et
al
grove
et
al
benefici
use
primari
secondari
heterohybridoma
fusion
partner
rather
mous
rat
myeloma
cell
line
doubt
whether
benefit
continu
accru
beyond
point
first
rodent
myeloma
cell
use
hybridoma
studi
secretor
immunoglobulin
result
hybridoma
could
potenti
produc
mix
ig
chain
deriv
parent
line
thu
reduc
chanc
isol
antibodi
molecul
compos
heavi
light
chain
lymphocyt
ig
et
al
later
avail
myeloma
neither
synthesis
secret
ig
overcam
problem
schulman
et
al
argument
appli
choic
fusion
partner
product
heterohybridoma
especi
import
rodent
ig
chain
secret
report
interspecif
fusion
date
use
polyethylen
glycol
peg
fuse
agent
peg
routin
use
although
peg
also
shown
satisfactori
fusion
techniqu
use
heterohybridoma
work
basic
modif
develop
murin
fusion
suggest
sogn
increas
exposur
time
peg
may
advantag
rabbit
x
mous
fusion
howev
cytotox
peg
dictat
exposur
time
kept
minimum
compat
effect
fusion
experi
min
exposur
peg
give
good
result
worker
plate
fuse
cell
directli
hat
medium
contain
serum
whilst
laboratori
make
use
feeder
cell
heterohybridoma
cultur
system
yarmush
et
al
guidri
et
al
van
meur
jonker
grove
et
al
other
found
necessari
beh
et
al
tucker
et
al
use
feeder
cell
follow
fusion
depend
dilut
fuse
cell
plate
sinc
higher
concentr
fuse
initi
act
feeder
cultur
condit
use
product
heterohybridoma
use
normal
hybridoma
inher
instabl
wise
fuse
larger
number
cell
set
cultur
plate
mous
x
mous
fusion
base
media
either
rpmi
van
meur
jonker
tucker
et
al
anderson
et
al
dmem
et
al
davidson
et
al
grove
et
al
mixtur
two
srikumaran
et
al
basal
medium
supplement
serum
use
rabbit
serum
product
rabbit
x
mous
heterohybridoma
report
improv
yield
stabl
antibodysecret
clone
raybould
takahashi
may
appli
speci
choic
serum
may
also
influenc
screen
assay
typic
serumsuppl
heterohybridoma
cell
supernat
contain
less
specif
antibodi
background
mgml
serum
protein
bovin
ovin
heterohybridoma
readili
adapt
varieti
differ
sera
serumsubstitut
well
sever
commerci
avail
serumfre
prepar
grove
et
al
grove
unpublish
data
latter
media
exhibit
earlier
sign
exhaust
compar
serumsuppl
media
antibodi
often
produc
lower
rate
fusion
effici
interspeci
fusion
similar
obtain
murin
fusion
howev
greater
genet
disrupt
interspeci
compar
intraspeci
fusion
result
frequent
report
poor
stabil
line
gener
import
clone
soon
possibl
identif
specif
antibodi
cultur
supernat
first
clone
stage
often
exhibit
low
effici
use
tri
clone
high
cell
concentr
initi
follow
secondari
clone
monoclon
assur
subsequ
clone
stage
maintain
antibodi
posit
line
care
monitor
cultur
first
month
reveal
declin
antibodi
secret
rate
indic
necess
reclon
loss
secret
clone
first
week
fusion
fairli
dramat
although
antibodi
detect
earli
stage
may
result
antibodi
product
residu
unfus
lymphocyt
stabil
cell
line
establish
earli
stage
line
gener
prove
robust
murin
hybridoma
cultur
storag
choic
screen
assay
select
interspecif
fusion
work
necessarili
vari
desir
end
product
studi
fusion
process
prepar
ig
isotyp
standard
situat
rapid
reliabl
specif
antibodi
assay
avail
requir
broad
ig
assay
describ
srikumaran
et
al
tucker
et
al
case
use
screen
use
system
crossreact
either
murin
immunoglobulin
avoid
expend
effort
possibl
revert
mous
line
davidson
et
al
immunoglobulin
present
supplement
serum
exampl
fetal
calf
serum
endogen
ig
level
interfer
assay
monoclon
cattl
sheep
ig
case
hors
serum
substitut
anderson
et
al
interfer
problem
also
reduc
elimin
use
assay
reagent
antibodi
rais
speci
provid
medium
supplement
serum
grove
clayton
unpublish
data
determin
class
nonmurin
antibodi
restrict
lack
avail
class
subclass
antibodi
reliabl
qualiti
situat
improv
interspecif
fusion
technolog
use
creat
librari
monoclon
immunoglobulin
use
standard
prepar
reagent
srikumaran
et
al
tabl
list
ig
class
mab
produc
date
heterohybridoma
cell
line
readili
propag
vivo
use
untreat
normal
mous
strain
tumour
fail
becom
establish
balb
c
mice
follow
inject
mous
human
ostberg
pursch
mous
x
cattl
kennedi
et
al
grove
tucker
unpublish
observ
heterohybridoma
cell
cell
probabl
reject
express
cell
surfac
antigen
nonmurin
partner
success
result
obtain
use
balbc
genet
athym
nude
mice
mous
x
human
abram
et
al
mous
x
cattl
grove
et
al
kennedi
et
al
mous
rabbit
sogn
hybrid
irradi
chemic
immunosuppress
weissman
et
al
ostberg
scid
mice
ware
et
al
could
also
use
raybould
et
al
b
suggest
use
suitabl
immunosuppress
calv
pig
product
larg
volum
ascit
contain
antibodi
deriv
speci
initi
attempt
grow
mous
cattl
heterohybridoma
cell
vivo
cow
calv
unsuccess
kennedi
et
al
although
gener
accept
establish
stabl
heterohybridoma
clone
difficult
murin
x
routin
hybridoma
jame
bell
reason
presum
result
line
less
robust
adapt
larg
scale
product
process
ostberg
almost
report
vitro
cultur
mabsecret
line
static
flask
system
scaleup
problem
similar
line
care
studi
mous
x
human
system
rang
differ
system
success
appli
includ
roller
bottl
ml
ostberg
ml
capac
thompson
et
al
spinner
flask
ml
kitano
et
al
thompson
et
al
perfus
system
use
hollow
fibr
modul
andersen
gruenberg
takazawa
et
al
jar
fermentor
kitano
et
al
mous
sheep
heterohybridoma
secret
igg
testosteron
success
grown
stir
flask
grove
et
al
mous
cattl
cattl
line
produc
testosteron
cultur
number
system
includ
stir
flask
volum
grove
murdin
unpublish
data
polyest
foam
matrix
packedb
bioreactor
total
medium
volum
ml
murdin
et
al
method
produc
similar
level
antibodi
obtain
static
flask
cultur
cell
densiti
sustain
suspens
cultur
also
similar
attain
static
flask
cultur
cultur
mous
x
cattl
cattl
heterohybridoma
also
sustain
larg
scale
hollow
fibr
bioreactor
endotron
junior
p
grove
unpublish
data
although
peak
cell
densiti
compar
cell
type
cellsml
readili
achiev
process
control
system
insuffici
develop
rais
antibodi
product
gml
mg
day
first
report
heterohybridoma
mostli
concern
product
monoclon
ig
undefin
specif
increas
number
paper
describ
success
product
mab
particular
antigen
current
list
shown
tabl
illustr
scope
potenti
techniqu
present
bovin
mab
use
cattl
bloodtyp
may
well
eventu
replac
convent
polyclon
reagent
expens
produc
difficult
standard
bovin
mab
provid
evid
exist
second
mhc
class
locu
cattl
kemp
et
al
other
use
experi
direct
toward
prevent
control
respiratori
syncyti
viral
infect
cattl
kennedi
et
al
bovin
mab
also
provid
standard
bovin
ig
isotyp
srikumaran
et
al
bovin
mab
testosteron
administ
vivo
initi
field
trial
studi
immunoneutralis
morri
rhind
clayton
grove
unpublish
data
ovin
mab
nematod
parasit
ostertagia
haemonchu
use
probe
defin
protect
antigen
view
vaccin
product
anderson
et
al
ovin
mab
progesteron
grove
et
al
current
develop
assay
reagent
antibodi
affin
report
case
presum
due
difficulti
measur
affin
virus
bacteria
erythrocyt
antigen
high
affin
bovin
ovin
mab
direct
steroid
reflect
better
polyclon
respons
speci
rel
murin
system
demonstr
one
advantag
nonrod
rodent
system
although
first
report
use
heterohybridoma
produc
mab
appear
time
human
veterinari
field
progress
date
much
rapid
former
latter
doubt
dictat
urgent
therapeut
need
howev
clear
nonrod
mab
veterinari
interest
import
play
futur
specif
case
requir
met
rodent
monoclon
antibodi
expans
work
srikumaran
cowork
srikumaran
cowork
srikumaran
cowork
characteris
bovin
ig
class
subclass
colleagu
studi
rabbit
ig
could
use
extend
speci
basic
investig
immun
system
prepar
isotop
standard
heterohybridoma
provid
materi
identif
medrano
dutrillaux
tucker
et
al
eventu
manipul
ig
gene
allow
engin
antibodi
improv
specif
effector
function
drastic
manipul
permit
gener
chimaer
antibodi
combin
compon
two
speci
oi
et
al
morrison
neuberg
therapeut
prophylact
prospect
human
mab
review
recent
larrick
bourla
idea
potenti
applic
veterinari
problem
sherman
markham
perhap
major
limit
develop
along
line
costbenefit
ratio
murin
mab
alreadi
use
passiv
immunis
protocol
sherman
et
al
replac
serum
therapi
eg
control
clostridi
diseas
sheep
may
prove
advantag
therapeut
area
mab
might
provid
treatment
choic
acut
toxin
venom
elimin
direct
blockad
viral
entri
specif
target
drug
link
directli
mab
especi
control
parasit
idiotyp
mab
great
potenti
vaccin
standard
approach
success
kennedi
et
al
exampl
antigen
undefin
particularli
difficult
prepar
possibl
advers
effect
use
attenu
microorgan
mab
use
way
may
also
benefit
immun
singl
defin
group
antigen
determin
requir
mab
may
also
utilis
modul
normal
physiolog
process
neutralis
circul
hormon
booman
receptor
site
action
without
produc
drug
residu
unwant
side
effect
antiidiotyp
mab
may
also
prove
use
surrog
hormon
date
nonrod
mab
produc
small
select
laboratori
farm
speci
develop
first
gener
techniqu
use
mous
myeloma
associ
suitabl
screen
assay
permit
product
mab
desir
speci
investig
immunolog
exot
speci
even
subject
control
breed
gener
may
reveal
import
new
inform
speci
gener
applic
mab
envisag
develop
heterohybridoma
fusion
partner
worthwhil
potenti
improv
stabil
predict
result
murin
mab
frequent
criticis
lack
effector
action
abil
fix
complement
poor
affin
rel
polyclon
antisera
speci
inde
substanc
poorli
immunogen
mice
rat
yet
produc
signific
respons
speci
interspecif
mab
technolog
use
immortalis
high
affin
antibodi
particular
specif
anim
defin
immunolog
perform
use
nondestruct
mean
lymphocyt
collect
allow
develop
declin
immun
respons
studi
also
repeat
collect
lymphocyt
individu
anim
identifi
good
polyclon
antisera
produc
mab
desir
characterist
isol
human
mab
product
increas
interest
primari
secondari
vitro
immun
read
jame
bell
claim
particularli
use
approach
weak
antigen
boss
area
worth
explor
veterinari
side
current
notabl
except
human
mab
term
monoclon
antibodi
gener
regard
synonym
product
murin
origin
possibl
antibodi
deriv
speci
acknowledg
full
potenti
mab
veterinari
therapeut
diagnost
emerg
applic
techniqu
describ
review
also
permit
investig
exploit
immunolog
characterist
wide
rang
differ
anim
speci
although
mice
continu
provid
indispens
research
tool
mab
work
envisag
interspecif
fusion
increasingli
reli
upon
provid
reagent
practic
commerci
applic
pilu
antigen
e
coli
produc
murinebovin
hybridoma
vet
im
